Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carole A Sable

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|October 2, 2004
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropeniaThomas J Walsh, Hedy Teppler, Gerald R Donowitz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2004
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapyJohan Maertens, Issam Raad, George Petrikkos, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescentsThomas J Walsh, Peter C Adamson, Nita L Seibel, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|October 2, 2004
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropeniaThomas J Walsh, Hedy Teppler, Gerald R Donowitz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2004
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapyJohan Maertens, Issam Raad, George Petrikkos, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescentsThomas J Walsh, Peter C Adamson, Nita L Seibel, et al.
Pageof 2